GenesisCare announces the addition of an 8th systemic anti-cancer therapy service in Surrey

Having recently announced a new Systemic Anti-Cancer Therapy (SACT) centre in Royal Tunbridge Wells, today GenesisCare confirms they will expand their UK network yet again with an additional SACT service at their centre in Surrey, opening Winter 2026.

GenesisCare, the UK’s leading cancer care provider, is delighted to announce plans to extend their existing specialist cancer care centre in Surrey to encompass a new Systemic Anti-Cancer Therapy (SACT) suite – the 8^th in their national network. As part of their ongoing commitment to expanding access to high-quality cancer care across the UK, the new service will provide patients from Surrey and surrounding areas with access to a full range of essential cancer treatments including chemotherapy, immunotherapy, and cellular therapy in a modern, purpose-built environment.  The centre will also become a research centre, enabling suitable patients to access innovative drug regimes that may not be easily available elsewhere.

GenesisCare has treated cancer patients in Surrey for over 13 years, and in 2024 moved to a new stand alone, state-of-the-art comprehensive oncology centre in Guildford, where advanced radiotherapy including MR Linac technology, diagnostic imaging, theranostics, well-being services and exercise medicine facilities are all available under one roof. Now, supported by the region’s leading clinicians, they will complete this oncology ecosystem with the addition of these SACT and research services.

GenesisCare has developed the largest family of oncology experts in the UK and is built upon the ethos of being a clinician-led organisation. This new SACT service epitomises that, powered by commitment and foresight of GenesisCare’s cancer experts including Dr Tony Dhillon, Consultant Medical Oncologist and Senior Lecturer in Oncology.  Dr Dhillon says “As a medical oncologist specialising in cancers of the gastrointestinal (GI) tract, I am passionate about caring for patients with colon, pancreas, liver and bile duct tumours and I witness every day the difference that timely access to expert, specialist treatment can make. The opening of this new GenesisCare SACT service marks an exciting and important milestone for our community, expanding access to world-class cancer services in a purpose-built, patient-centred environment. I am proud to be part of this new chapter. At GenesisCare, we are committed not only to delivering the highest standard of evidence-based therapies, but also to ensuring that each patient feels supported, informed, and cared for throughout their treatment journey. Alongside state-of-the-art facilities and a multidisciplinary approach, we will continue to strengthen our involvement in GI cancer research.

Additionally, Dr Panos Koliou, who specialises in the treatment and research of breast cancer said:  “As a consultant in medical oncology, treating patients with both early and metastatic breast cancer, I see every day how important timely access to high-quality, specialist care is. The opening of this new SACT service at GenesisCare in Surrey represents a significant step forward for our patients, and I’m very much looking forward to being part of this latest phase of growth. In addition to delivering evidence-based treatment in a modern, supportive environment, we will also be advancing research in breast cancer, helping to bring innovative therapies and clinical trials to our patients while maintaining the personalised care they value.”

With systemic anti-cancer therapy services now available in 8 GenesisCare centres including Bristol, Oxford, Milton Keynes, Windsor, Guildford, Royal Tunbridge Wells, Maidstone and Cambridge, patients from across the entire South of England can readily access GenesisCare quality care without the need for excessive travel, which can often be difficult during treatment for the patient and their families.  GenesisCare is committed to increasing access to its services and has further expansion plans for its world-leading and pioneering cancer services throughout the UK which will be announced in due course.